Med. Pro Praxi 2006; 4: 169-171 [Interní Med. 2006; 8(5): 219-222]

Diabetes mellitus a hypertenze

MUDr. Erik Hollay1, MUDr. Pavlína Pi»hová2, doc. MUDr. Milan Kvapil CSc2
1 Diabetologické centrum, Interní klinika 2. LF UK a FN Motol, Praha
2 Interní klinika fakultní nemocnice Motol a 2. lékařské fakulty Univerzity Karlovy v Praze

Arteriální hypertenze je vzhledem k vysoké prevalenci ve vyspělých zemích stále aktuálním problémem. Je povaľována za jednu ze součástí metabolického syndromu a patří k  nejzávaľnějąím rizikovým faktorům kardiovaskulární morbidity a mortality. V tomto článku se autoři pokouąejí o shrnutí postupů k léčbě arteriální hypertenze u diabetiků v souvislosti s výstupy provedených studií.

Keywords: diabetes mellitus 1. a 2. typu, hypertenze, léčba nefarmakologická, antihypertenziva, inhibitory ACE, antagonisté receptoru pro angiotenzin II, betablokátory, blokátory kalciových kanálů

Published: October 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Hollay E, Pi»hová P, Kvapil M. Diabetes mellitus a hypertenze. Med. praxi. 2006;3(4):169-171.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cífková R et al. za Českou společnost pro hypertenzi: Doporučení diagnostických a léčebných postupů u arteriální hypertenze - verze 2004. Doporučení České společnosti pro hypertenzi. Vnitřní lék 2004; 9: 709-722.
    2. Deedwania PC. Hypertension and diabetes: New therapeutic options. Arch Intern Med 2000; 160: 1585-1594. Go to original source... Go to PubMed...
    3. Haffner SM et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without previous myocardial infarction implications treatment of hyperlipidemia in diabetic subjects without prior myocardial infarction. N Engl J Med 1998; 339: 229-234. Go to original source... Go to PubMed...
    4. Hansson L et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular mortality and morbidity in hypertension: the Captopril Prevention Project (CAPP). Lancet 1999; 353: 611-616. Go to original source... Go to PubMed...
    5. Charvát J et al. Diabetes mellitus a makrovaskulární komplikace. Praha: Triton 2001: 203.
    6. Lindholm LH et al. Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hyperten 2002; 20: 1879-1886. Go to original source... Go to PubMed...
    7. Ruggenetenti P et al. Preventing Microalbuminuria in Type 2 Diabetes. N Engl J Med 2004; 351: 1941-1951. Go to original source... Go to PubMed...
    8. The Antihypertensive and Lipid - Lovering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 1981-1997.
    9. The Seventh Report of the JNC onprevention, Detection, Evaluation and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
    10. UK Prospective Diabetes Study (UKPDS) Group. Efficiacy of atenolol and captopril in reducing risk of macrovascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720. Go to original source...
    11. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or inzulín compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853. Go to original source...
    12. Widimský J et al. Hypertenze. 2. vydání, Praha: Triton 2004.
    13. Working Party of the International Diabetes Federation. Hypertension in people with Type 2 Diabetes: knowledge-based diabetes-specific guidelines. Diabetic Medicine 2003; 20: 972-987. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.